Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Palatin Technologies Inc PTN

Healthcare Biotechnology
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with unmet medical need and commercial potential. Its new product development activities focus primarily on MC1r agonists... see more

Recent & Breaking News (NYSEAM:PTN)

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

PR Newswire April 8, 2024

Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

PR Newswire February 28, 2024

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

PR Newswire February 15, 2024

Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024

PR Newswire February 9, 2024

Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

PR Newswire February 5, 2024

Palatin Announces Closing of $10 Million Registered Direct Offering

PR Newswire February 1, 2024

Palatin Announces $10 Million Registered Direct Offering

PR Newswire January 30, 2024

Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024

PR Newswire January 8, 2024

Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

Business Wire January 3, 2024

Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million

PR Newswire December 20, 2023

Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

PR Newswire December 18, 2023

Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

PR Newswire November 14, 2023

Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023

PR Newswire November 9, 2023

Palatin Announces Closing of $5 Million Registered Direct Offering

PR Newswire October 24, 2023

Palatin Announces $5 Million Registered Direct Offering

PR Newswire October 23, 2023

Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results

PR Newswire October 19, 2023

Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients

PR Newswire October 18, 2023

Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment

PR Newswire October 16, 2023

Palatin Receives Notice of Non-Compliance from NYSE American

PR Newswire October 13, 2023

Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update

PR Newswire September 28, 2023